Glyscend Inc
Oral pill that mimics bariatric surgery effects using a dynamic barrier mechanism
- Sector
- Biotech
- Headquarters
- BALTIMORE, MD
- Latest Form D
- $4.8M, Feb 2020
- Total capital
- $5.5M
- Federal grants
- $725K
- 2 awards · 2015–2017
- Rank in peer group#1 of 20
- Private capital raised
- $4.8M
- 1 Form D · last Feb 2020
- 80 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 10 pending · first 2022
- Rank in peer group#2 of 20
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$4.8M
- Federal grantNSF · Phase II · SBIR Phase II: Orally-dosed Intestinal Coating for the Treatment of Type 2 Diabetes Inspired from Bariatric Surgery$500K
- Federal grantNSF · Phase I · STTR Phase I: Feasibility and proof of concept of a non-invasive treatment for type 2 diabetes inspired from bariatric surgery$225K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
56months
from Glyscend Inc’s first federal award to its first private round.
- First federal award · Jun 2015
- NSF · $225K
- First Form D · Feb 2020
- $4.8M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 20 peers
Line = medianBiotech · Material
- Federal grants#1 · top 5%
- Granted patents#2 · top 10%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ashish NimgaonkarExecutive Officer, DirectorNamed in SEC Form D filings
- Bob SohDirectorNamed in SEC Form D filings
- Casey CunninghamDirectorNamed in SEC Form D filings
- Dennis McWilliamsDirectorNamed in SEC Form D filings
- Leighton ReadDirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 15- PendingSubstituted Phenyl Boronic Acid Containing Polymers And Methods Of UseUSPTOApplication 18756151
- GrantedSubstituted Phenyl Boronic Acid Containing Polymers And Methods Of UseUSPTOUS 12,059,432
- PendingSubstituted Phenyl Boronic Acid Containing Polymers And Methods Of UseUSPTOApplication 18151604
Show all 15 patent records
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseJan 30, 2025 · Application 18756151Pending
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseAug 13, 2024 · US 12,059,432Granted
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseOct 26, 2023 · Application 18151604Pending
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseFeb 14, 2023 · US 11,576,928Granted
- Benzoxaborole Polymers And Methods Of UseDec 15, 2022 · Application 17642807Pending
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseNov 8, 2022 · US 11,491,183Granted
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseNov 8, 2022 · US 11,491,182Granted
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseNov 1, 2022 · US 11,484,548Granted
- Boronic Acid Polymers And Methods Of UseDec 30, 2021 · Application 17277702Pending
- Benzoxaborole Polymers And Methods Of UseApplication 62903332Pending
- Boronic Acid Polymers And Methods Of UseApplication 62734054Pending
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseApplication PCTUS2020051506Pending
- Benzoxaborole Polymers And Methods Of UseApplication PCTUS2020051499Pending
- Boronic Acid Polymers And Methods Of UseApplication PCTUS2019052110Pending
- Substituted Phenyl Boronic Acid Containing Polymers And Methods Of UseApplication 62903328Pending
Related companies, and why
- Go Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- OPAL THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
- GlycomineSimilar federal contract value in Biotech · null in contracts
- Spectrum Antimicrobials, Inc.Similar federal contract value in Biotech · null in contracts
- Lipidio Pharmaceuticals Inc.Similar federal contract value in Biotech · null in contracts
- IO THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .